Back to Results
First PageMeta Content
Blood / Deep vein thrombosis / Low molecular weight heparin / Warfarin / Pulmonary embolism / Venous thrombosis / Thrombosis / Anticoagulant / Aspirin / Hematology / Medicine / Heparins


Barriers in VTE Prevention: Impact on Therapeutic Choice and Duration Mary Ellen McCann, RN MA, National Blood Clot Alliance, Tarrytown, NY; Alan P. Brownstein, MPH, National Blood Clot Alliance, Tarrytown, NY Background
Add to Reading List

Document Date: 2015-03-11 17:55:47


Open Document

File Size: 736,85 KB

Share Result on Facebook

City

Tarrytown / /

Company

USA/Direct Inc. / Ortho-McNeil-Janssen Pharmaceuticals Inc. / /

Country

United States / /

IndustryTerm

Internet research panel / travel blood test / Internet survey / /

MarketIndex

DVT/PE / /

MedicalCondition

Deep vein thrombosis / blood clot / venous thromboembolism / pulmonary embolism / Prevent Deep Vein Thrombosis / /

MedicalTreatment

knee replacement / /

Organization

Division of Ortho-McNeil-Janssen Pharmaceuticals / National Institute of Health / National Blood Clot Alliance / /

Person

Mary Ellen McCann / Alan P. Brownstein / /

Position

surgeon / Aspirin Patient Reported Warfarin Barriers Surgeon / The Surgeon General / INR monitoring THA/TKA SURGEONS Bleeding Drug interactions Remember Tx Dose Change Surgeon / Surgeon General / /

Product

Tx / /

ProvinceOrState

Prince Edward Island / New York / /

URL

www.surgeongeneral.gov/topics/deepvein/calltoaction/call-to-action-on-dvt-2008.pdf / /

SocialTag